Disappointing RethinQ Data Is Neither Plus Nor Minus For ICDs – Analysts
This article was originally published in The Gray Sheet
Executive Summary
The St. Jude-sponsored RethinQ trial will not expand the market for cardiac resynchronization therapy defibrillators as the company had hoped, but will not do further damage to the sluggish ICD market, analysts project
You may also be interested in...
7-French Factor: Absence Of Fidelis Lead Gives St. Jude’s Riata A Boost
Medtronic's recall of its Sprint Fidelis ICD leads will have only a small impact on overall implantable defibrillator demand, but the market leader's share will suffer as doctors seek the thinnest leads available, electrophysiologists suggested on an Oct. 29 conference call
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.